Phase I, Monocentric, Double-blind, Randomized Study to Assess Tolerability, Safety and Pharmacokinetics of ACH15 After Single Dose and Multiple Doses in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 21 Oct 2016
At a glance
- Drugs ACH 15 (Primary)
- Indications Inflammation
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Ache Laboratories
- 18 Oct 2016 Planned End Date changed from 1 Apr 2014 to 1 Jun 2017.
- 18 Oct 2016 Status changed from not yet recruiting to discontinued.
- 10 Apr 2014 New trial record